Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Non-Current Debt (2016 - 2023)

Historic Non-Current Debt for Angiodynamics (ANGO) over the last 15 years, with Q2 2023 value amounting to $49.8 million.

  • Angiodynamics' Non-Current Debt rose 9927.2% to $49.8 million in Q2 2023 from the same period last year, while for May 2023 it was $49.8 million, marking a year-over-year increase of 9927.2%. This contributed to the annual value of $49.8 million for FY2023, which is 9927.2% up from last year.
  • Per Angiodynamics' latest filing, its Non-Current Debt stood at $49.8 million for Q2 2023, which was up 9927.2% from $49.8 million recorded in Q1 2023.
  • Angiodynamics' Non-Current Debt's 5-year high stood at $126.8 million during Q1 2019, with a 5-year trough of $14.3 million in Q1 2020.
  • In the last 5 years, Angiodynamics' Non-Current Debt had a median value of $40.0 million in 2020 and averaged $45.9 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first plummeted by 8869.34% in 2020, then skyrocketed by 10919.04% in 2021.
  • Angiodynamics' Non-Current Debt (Quarter) stood at $124.4 million in 2019, then crashed by 67.85% to $40.0 million in 2020, then plummeted by 37.5% to $25.0 million in 2021, then skyrocketed by 99.18% to $49.8 million in 2022, then increased by 0.04% to $49.8 million in 2023.
  • Its Non-Current Debt was $49.8 million in Q2 2023, compared to $49.8 million in Q1 2023 and $49.8 million in Q4 2022.